Leukemia: Chronic Myeloid Leukemia (CML)

    Actionable Target Abnormality Clinical Experience with Targeted Agent
    Tyrosine kinase BCR-ABL Imatinib (BCR-ABL inhibitor):
    • Phase 2: Complete cytogenetic responses (CCyRs) 41%, complete hematologic response 95%, PFS 89% at 18 mo (28)
    Dasatinib (BCR-ABL, SRC inhibitor):
    • Phase 3: CCyRs 86%, major molecular response (MMR) 64% at 24 mo, transformation to accelerated/blast phase 2.3% (29)
    Nilotinib (BCR-ABL inhibitor):
    • Phase 3:
    • 300 mg BID: CCyRs 87%, MMR 71% at 24 mo, complete molecular response (reduction of BCR-ABL levels to ≤0.0032%) 26%, 24-mo OS (CML-related deaths) 98.9%
    • 400 mg BID: CCyRs 85%, mplete molecular response (reduction of BCR-ABL levels to ≤0.0032%) 21%, 24-mo OS (CML-related deaths) 98.9% (30)
    Other topics in Targets by Organ Site